"1As part of the transaction, AbbVie gains ImmunoGen's flagship ADC Elahere (mirvetuximab soravtansine-gynx). Beyond Elahere, ImmunoGen's Phase I next-generation anti-FRα ADC, IMGN-151, is being evaluated for the treatment of ovarian cancer with the potential to expand into other solid tumor types. AbbVie said the acquisition of ImmunoGen will be accretive to the company’s diluted EPS starting in 2027 and significantly accretive over the long-term. AbbVie Completes Acquisition of ImmunoGen. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio.

Source: Wall Street Journal February 13, 2024 06:46 UTC